Skip to main content

Table 1 Operating characteristics for the platform design with primary endpoint of major pathological response (MPR)

From: PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer

  Control Arm n = 30 for experimental arms
Experiment Arm 1 Experiment Arm 2 Experiment Arm 3 Experiment Arm 4
True MPR 0.130 0.195 0.260 0.130 0.300
Number of patients 42.6 30.0 30.0 30.0 30.0
Start Time (months) 0 0 6 12 18
Probability of claiming success 0.384 0.676 0.148 0.800